Kevin Feeley Sells 3,749 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 3,749 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $96.71, for a total value of $362,565.79. Following the completion of the sale, the chief financial officer now directly owns 8,492 shares in the company, valued at approximately $821,261.32. This trade represents a 30.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Thursday, March 13th, Kevin Feeley sold 402 shares of GeneDx stock. The shares were sold at an average price of $90.05, for a total value of $36,200.10.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The stock was sold at an average price of $94.72, for a total transaction of $87,331.84.
• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total transaction of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The shares were sold at an average price of $93.82, for a total transaction of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The stock was sold at an average price of $76.04, for a total value of $108,737.20.

GeneDx Stock Performance

Shares of NASDAQ WGS opened at $97.44 on Thursday. GeneDx Holdings Corp. has a 1 year low of $8.03 and a 1 year high of $115.60. The firm has a market cap of $2.73 billion, a P/E ratio of -49.71 and a beta of 1.91. The stock has a fifty day moving average price of $84.59 and a two-hundred day moving average price of $70.97. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40.

GeneDx (NASDAQ:WGS) last announced its earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The business had revenue of $95.64 million during the quarter, compared to analysts’ expectations of $82.24 million. Research analysts forecast that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Hedge Funds Weigh In On GeneDx

Several hedge funds have recently made changes to their positions in WGS. Vanguard Group Inc. boosted its holdings in GeneDx by 18.5% during the fourth quarter. Vanguard Group Inc. now owns 1,006,210 shares of the company’s stock worth $77,337,000 after buying an additional 156,768 shares in the last quarter. Summit Partners Public Asset Management LLC lifted its position in shares of GeneDx by 336.9% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 755,564 shares of the company’s stock valued at $58,073,000 after acquiring an additional 582,619 shares during the last quarter. William Blair Investment Management LLC bought a new stake in shares of GeneDx during the 4th quarter worth $51,496,000. Lord Abbett & CO. LLC acquired a new position in shares of GeneDx in the 4th quarter worth $48,458,000. Finally, Fred Alger Management LLC raised its position in shares of GeneDx by 38.5% during the fourth quarter. Fred Alger Management LLC now owns 546,054 shares of the company’s stock worth $41,970,000 after purchasing an additional 151,824 shares during the period. Institutional investors and hedge funds own 61.72% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. The Goldman Sachs Group lifted their target price on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research note on Wednesday, February 19th. TD Cowen raised their price target on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, GeneDx currently has an average rating of “Moderate Buy” and a consensus price target of $72.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.